Related Experiment Videos
Adenovirus-mediated p53 gene therapy for human gliomas
1Department of Neurosurgery, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Objective:
The rationale and current evidence for using p53 gene replacement as a potential treatment for human gliomas are reviewed. The possible benefits of and obstacles to this approach are delineated.
Methods:
One approach to overcoming the poor outcomes associated with conventional glioma therapies involves the replacement of tumor suppressor genes that are fundamental to glioma development. The p53 gene is one of the most frequently mutated genes in human gliomas, and loss of p53 function is critical to the development of glial neoplasms. Consequently, replacement of the p53 gene using viral vectors may be a potential treatment for human gliomas.
Results:
In vitro studies demonstrate that adenovirus-mediated p53 gene transfer into gliomas with mutant p53 results in massive apoptosis. Similarly, transfer of p53 inhibits tumor growth in vivo. In contrast to mutant p53 gliomas, wild-type p53 glioma cells are resistant to the apoptotic effects of p53 transfer, but this resistance can be overcome by the addition of deoxyribonucleic acid-damaging agents such as ionizing radiation or chemotherapy. The main obstacle to p53 gene therapy involves the limitations associated with current modes of delivery.
Conclusion:
Preclinical data strongly support the use of p53 gene transfer as a potential treatment for human gliomas.
Insights
p53 gene replacement shows promise for treating human gliomas by inducing apoptosis and inhibiting tumor growth. Further research is needed to overcome delivery challenges for this potential glioma therapy.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Gliomas are primary brain tumors with poor prognoses, often linked to mutations in tumor suppressor genes.
- The p53 tumor suppressor gene is frequently mutated or inactivated in human gliomas, playing a critical role in glial neoplasm development.
- Conventional glioma therapies have limited efficacy, necessitating novel treatment strategies.
Purpose of the Study:
- To review the rationale and current evidence for p53 gene replacement as a potential therapeutic strategy for human gliomas.
- To delineate the potential benefits and obstacles associated with p53 gene therapy in glioma treatment.
Main Methods:
- Utilizing viral vectors, specifically adenovirus, for the transfer of the p53 gene into glioma cells.
- Evaluating the effects of p53 gene transfer on glioma cells in vitro and in vivo.
- Investigating the impact of combining p53 gene transfer with DNA-damaging agents like radiation and chemotherapy.
Main Results:
- Adenovirus-mediated p53 gene transfer into gliomas with mutant p53 induced massive apoptosis in vitro.
- p53 gene transfer demonstrated inhibition of tumor growth in vivo.
- Wild-type p53 glioma cells exhibited resistance to p53 transfer-induced apoptosis, which was overcome by co-administration of DNA-damaging agents.
Conclusions:
- Preclinical data provide strong support for p53 gene transfer as a viable therapeutic approach for human gliomas.
- The primary challenge for clinical application of p53 gene therapy lies in optimizing gene delivery methods.